CD19 and diffuse large B-cell lymphoma: Notably, CAR-T therapy with the most investigated target thus far, CD19, is a promising therapy for hematologic cancer and has dramatically improved the treatment of lymphoid malignancies, predominantly diffuse large B-cell lymphoma (DLBCL) and acute lymphoblastic leukemia (ALL).